AbbVie signs $2.9bn deal with I-Mab for ‘don’t eat me’ cance...

AbbVie has claimed rights to an immuno-oncology antibody from I-Mab in what is thought to be a record licensing deal involving a Chinese biotech.

Latecomer Lilly throws cash at Innovent PD-1 partnership

Eli Lilly has doubled down on its partnership with Chia’s Innovent with a licensing deal for ex-China rights to Tyvyt, their PD-1 inhibitor, which some analysts think may be la

Roche doubles down on tau for Alzheimer’s, licensing UCB dru...

Roche already has one Alzheimer’s candidate in its pipeline targeting tau, but has added a second via a deal with Belgian drugmaker UCB worth up to $2 billion.

Roche hops on Bicycle’s drug discovery platform for cancer

Neurocrine signs $400M-plus deal with Idorsia for epilepsy d...

Roche swoops on Dicerna’s gene-silencing hepatitis B drug